ππ
#deucravacitinibSmPC for SOTYKTU 6 mg film-coated tablets has been updated with changes to sections 3. Pharmaceutical form; 5.1 Pharmacodynamic properties; 6.3 Shelf life; 10. Date of revision of the text on 05/08/2024.
π
https://www.medicines.org.uk/emc/product/14871/smpcChange log:
https://www.medicines.org.uk/emc/product/14871/smpc/historySOTYKTU 6 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc)
SOTYKTU 6 mg film coated tablets - Summary of Product Characteristics (SmPC) by Bristol Myers Squibb Pharmaceuticals limited
I'm now keeping an eye on: The SmPC for SOTYKTU 6 mg film coated tablets
πBristol Myers Squibb Pharmaceuticals limited
ππ #deucravacitinib.
I will let you know if it changes.
π https://www.medicines.org.uk/emc/product/14871/smpc
SOTYKTU 6 mg film coated tablets - Summary of Product Characteristics (SmPC) - (emc)
SOTYKTU 6 mg film coated tablets - Summary of Product Characteristics (SmPC) by Bristol Myers Squibb Pharmaceuticals limited
Hilft das Psoriasis-Medikament #Deucravacitinib zum Einnehmen besser als Mittel zum Spritzen? Das ist unklar. Wie auch die Langzeitsicherheit. (β¬)
https://gutepillen-schlechtepillen.de/neues-psoriasis-medikament-deucravacitinib/
Neues Psoriasis-Medikament Deucravacitinib - Gute Pillen - Schlechte Pillen
Hilft das Psoriasis-Medikament Deucravacitinib zum Einnehmen besser als Mittel zum Spritzen? Das ist unklar. Wie auch die Langzeitsicherheit.
Hilft das Psoriasis-Medikament #Deucravacitinib zum Einnehmen besser als Mittel zum Spritzen? Das ist unklar. Wie auch die Langzeitsicherheit. (β¬)
https://gutepillen-schlechtepillen.de/neues-psoriasis-medikament-deucravacitinib/
Neues Psoriasis-Medikament Deucravacitinib - Gute Pillen - Schlechte Pillen
Hilft das Psoriasis-Medikament Deucravacitinib zum Einnehmen besser als Mittel zum Spritzen? Das ist unklar. Wie auch die Langzeitsicherheit.
#rheumtwitter #sarcoid #rheumatology #Deucravacitinib
---
RT @SteZhao
π¨TYK2 inhibition is associated with reduced risk of sarcoidosis.
Suggesting that #TYK2 inhibitors eg #deucravacitinib - trialed for psoriasis/PsA - may be worth testing for treatment of #sarcoidosis - chronic condition for which few drugs are approved.
https://ard.bmj.com/content/82/3/445
https://twitter.com/SteZhao/status/1639640115092893696
Genetically proxied TYK2 inhibition is associated with reduced sarcoidosis susceptibility
Sarcoidosis is a multisystem inflammatory disorder of unknown aetiology that can affect any organ, including the lung, joints and skin. Clinical presentation can be highly heterogeneous and lead to significant morbidity and mortality.1 Glucocorticoids remain the cornerstone of pharmacological therapy but are limited by toxicities with long-term use. Although steroid-sparing agents are available, there are no licensed therapeutics for sarcoidosis. Many cytokines implicated in sarcoidosis (eg, gamma interferon and other type 1 cytokines) signal via the JAK-STAT pathway, and inhibition of this pathway has proved successful in several immune-mediated inflammatory diseases (IMIDs). Interestingly, tofacitinib, a JAK-STAT inhibitor, was associated with skin improvement and suppression of type 1 cytokines in an open-label trial of 10 patients with cutaneous sarcoidosis.2 However, these preliminary findings await confirmation by phase III trials and are caveated by tofacitinibβs potential adverse cardiovascular profile.
Inhibition of TYK2, one member of the JAK family, has shown promise for IMIDs (eg, deucravcitinib for psoriasis and psoriatic arthritis (PsA)).3 Germline mutations causing loss-of-function of genes encoding drug targets have been used to correctly predict the effect of their pharmacological inhibition4; therefore, we used a naturally occurring loss-of-function mutation to evaluate the therapeutic potential β¦
SPC Chemo Bot
Gute Pillen β Schlechte Pillen
May Kazem